# Irinotecan for Advanced and Metastatic Breast Cancer

> **NCT03562390** · PHASE2 · UNKNOWN · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 124 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03562390
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-01
- **Primary completion:** 2020-01
- **Final completion:** 2021-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562390, "Irinotecan for Advanced and Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03562390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*